RIDDLE&CODE
RIDDLE&CODE Energy Solutions, a subsidiary firm of the leading European blockchain interface company RIDDLE&CODE, together with the largest energy provider in Austria, Wien Energie, have announced the successful launch of a blockchain-powered energy tokenization platform called MyPower. The platform puts everyday consumers in charge of a co-created energy future by offering micro-investments and the tokenization of produced kilowatt-hours (kWh).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210607005004/en/
“Local energy communities and microgrids are expected to play an increasingly important role in addressing climate change challenges and the transition towards renewable and sustainable energy systems,” said Michael Strebl, CEO of Wien Energie. “However, the current market structure is inadequate to realise this vision, as consumers are practically excluded from participating in energy production and settlements. Blockchain has the potential to transform consumers into prosumers and active participants in the energy network.”
With the MyPower platform, which combines RIDDLE&CODE’s deep next-gen technology expertise with Wien Energie’s industry know-how, the two companies have managed to bridge this gap. As part of the project, RIDDLE&CODE Energy Solutions provides key management, tokenization and custody services and utilises Intel® Software Guard Extensions (Intel® SGX) to deliver the highest level of security.
The blockchain-powered platform enables consumers to participate in both energy consumption and production and benefit from using green energy. MyPower tokenizes solar photovoltaic (PV) assets and allows consumers to purchase shares in PV plants across Austria. At the MVP stage of the project, shares of a small, local PV plant were sold to a limited number of consumers. In return for their participation, consumers received a certain number of tokens, based on the amount of energy produced by the PV plant. The accumulated tokens could then be used for various purposes, such as paying electric bills.
“Confidential computing with Intel® Software Guard Extensions enables companies to leverage the benefits of confidential computing and allows data owners to remain in control of their sensitive data,” says Paul O’Neill, Senior Director, Business Development in Intel’s Confidential Computing Group. “RIDDLE&CODE's launch with Wien Energy demonstrates how Intel® SGX can help to deliver the security foundation needed to build and deploy a new era of dynamic and cost-effective networks. Intel® SGX offers hardware-based memory encryption that isolates specific application code and data in memory. Intel® SGX allows RIDDLE&CODE to allocate private regions of memory, called enclaves, which are designed to be protected from processes running at higher privilege levels.”
“Through the tokenization of both digital and physical assets, RIDDLE&CODE enables new business models in the financial, mobility and, of course, energy industries,” said Thomas Fürstner, Founder and CTO of RIDDLE&CODE. “Together with Wien Energie, we will unlock the full potential of the energy marketplaces and provide consumers with a platform that is both flexible and trustworthy.”
Please download related images to use in your articles from www.riddleandcode.com//press-mypower .
RIDDLE&CODE Energy Solutions
RIDDLE&CODE Energy Solutions, a subsidiary firm of the leading European blockchain interface company RIDDLE&CODE, provides the blockchain-powered infrastructure that enables resilient, low-cost and green electricity production and builds a foundation for a decentralised urban energy marketplace.
More information: www.riddleandcode.com
Wien Energie
Wien Energie is one of Austria’s largest utility providers, responsible for ensuring the reliable and eco-friendly supply of electricity, natural gas and heating to around two million people, 230,000 businesses and industrial facilities, and 4,500 farms in the Greater Vienna metropolitan area. Wien Energie is also involved in a number of projects at European level.
More information: www.wienenergie.at .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210607005004/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Curing the Incurable with ‘Biological Age Zero’ Cells: Clonell™ Launches the Ultimate Regenerative Medicine Platform5.1.2026 14:00:00 CET | Press release
Fundamental Cure for Intractable and Incurable Diseases using ‘Biological Age Zero’ Cells Derived from Patient’s Own Cells via SCNT TechnologyWorld's First Therapy Platform Simultaneously Solving Immune Rejection and Inheritance of Cellular Aging—The Major Hurdles of Existing Stem Cell TherapiesDrastically Improving Treatment Accessibility through the New Paradigm, ‘Patient-Initiated Clinical Trial™’, which Overcomes Existing Clinical Limitations Clonell Therapeutics, Inc., a leading biotechnology company dedicated to curing intractable and incurable diseases, announced today the official launch of the world's first 'Patient-Specific Embryonic Stem Cell (Somatic Cell Nuclear Transfer-derived Embryonic Stem Cell, hereinafter SCNT-ESC)' therapy platform based on Somatic Cell Nuclear Transfer (SCNT) technology. Concurrently, the company has initiated its innovative 'Patient-Initiated Clinical Trial™' to apply this breakthrough technology directly to patients. This platform launch is evalu
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq5.1.2026 13:30:00 CET | Press release
Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company Helus Pharma commences trading on Nasdaq Global Market (“Nasdaq”) and on Cboe Canada under ticker symbol: HELP Helus Pharma continues to progress its portfolio of novel serotonergic agonists (“NSAs”), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 Preparations in progress for the commercialization of HLP003, Helus Pharma’s NSA in Phase 3 clinical development, which has been granted Breakthrough Therapy Designation by the FDA for the adjunctive treatment of major depressive disorder This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated Sep
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma5.1.2026 13:30:00 CET | Press release
- Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP met its primary endpoint of progression-free survival (PFS) - Based on these results, Incyte plans to file a supplemental Biologics License Application (sBLA) for tafasitamab and lenalidomide in addition to R-CHOP in first-line diffuse large B-cell lymphoma (DLBCL) in the first half of 2026 Incyte (Nasdaq:INCY) today announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, and lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) compared to R-CHOP alone as a first-line treatment for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of three to five (3-5) for patients >60 years o
SBC Medical Accelerates Global Expansion with Strategic Investment and Alliance witha Leading U.S. MedSpa Platform OrangeTwist as Part of Broader Growth Strategy5.1.2026 13:00:00 CET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to medical corporations and their clinics, today announced the completion of a strategic minority equity investment and the establishment of a structured collaboration framework with OrangeTwist, a leading U.S.-based MedSpa chain, alongside its longstanding institutional shareholders, Hildred Capital and Athyrium Capital. This transaction marks SBC Medical’s formal entry into the United States—a key global market for medical aesthetics—and represents a major milestone in the Company’s broader global expansion strategy. For more details, click here. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251210926005/en/ OrangeTwist Supporting 258 affiliated clinics worldwide and managing more than six million patient visits annually, SBC Medical has built one of the largest and
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)5.1.2026 13:00:00 CET | Press release
Rusfertide Is a First-in-Class Investigational Hepcidin Mimetic That Targets Red Blood Cell Overproduction (Erythrocytosis) in Polycythemia Vera NDA Includes 52-Week Data from Phase 3 VERIFY Study, Which Met the Primary and All Four Key Secondary Endpoints, Showing Rusfertide Provided Durable and Sustained Hematocrit Control and Improved Pre-Specified Patient Reported Outcome Measures Data Underscore the Potential to Shift the Treatment Paradigm for PV Patients to Reduce the Burden of Frequent Phlebotomies and Meaningfully Improve Hematocrit Control Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of rusfertide for the treatment of adults with polycythemia vera (PV). Rusfertide is an investigational first-in-class subcutaneously administered hepcidin mimetic peptide designed to regulate iron homeostasis and red blood cell product
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
